Literature DB >> 6326152

Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor.

R C Gaillard, P Schoenenberg, C A Favrod-Coune, A F Muller, J Marie, J Bockaert, S Jard.   

Abstract

Crude plasma membrane fractions were prepared from female Wistar rat anterior pituitaries. These fractions contained a single population of specific 3H-labeled [8-lysine]vasopressin [( 3H]vasopressin) binding sites with a dissociation of constant (Kd) of 8 +/- 2 X 10(-9) M and maximal binding capacity of 244 +/- 45 fmol/mg of protein. The Kd values for a series of vasopressin structural analogues with selective vasopressor or antidiuretic activities were determined together with the corresponding corticotropin-releasing activities (isolated perfused pituitary cells were used). A good correspondence was found between the two sets of values, suggesting that the detected vasopressin binding sites are the receptors involved in vasopressin-induced corticotropin release. The order of potency of these analogues for the binding to hypophysial receptors was similar to that found for the binding to the receptors involved in the vasopressor response. Corticotropin-releasing factor and angiotensin did not affect vasopressin binding to pituitary membranes. Median eminence extracts inhibited [3H]vasopressin binding with an efficiency very close to that expected from their vasopressin content. Corticotropin-releasing factor activated, and angiotensin inhibited, the adenylate cyclase activity of pituitary membranes. Under the same experimental conditions, vasopressin did not influence adenylate cyclase activity nor did it affect the corticotropin-releasing factor-induced activation. These data support the view that vasopressin is one component of the multifactorial regulation of corticotropin release and that it acts through a cAMP-independent pathway. The potentiation by vasopressin of corticotropin-releasing factor-induced cAMP accumulation in intact cells very likely proceeds through indirect mechanisms, which are not expressed in broken cell preparations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326152      PMCID: PMC345182          DOI: 10.1073/pnas.81.9.2907

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  The ACTH-releasing hormone of the hypothalamus requires a co-factor.

Authors:  A F Pearlmutter; E Rapino; M Saffran
Journal:  Endocrinology       Date:  1975-11       Impact factor: 4.736

2.  Use of (-)-[3H]dihydroalprenolol to study beta adrenergic receptor-adenylate cyclase coupling in C6 glioma cells: role of 5'-guanylylimidodiphosphate.

Authors:  M Lucas; J Bockaert
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

3.  A semi-automated in vitro assay for CRF: activities of peptides related to oxytocin and vasopressin.

Authors:  A F Pearlmutter; E Rapino; M Saffran
Journal:  Neuroendocrinology       Date:  1974       Impact factor: 4.914

4.  Isolated pituitary cells: CRF-like activity of neurohypophysial and related polypeptides.

Authors:  R Portanova; G Sayers
Journal:  Proc Soc Exp Biol Med       Date:  1973-07

5.  Effects of 8-lysine-vasopressin and synthetic analogues of release of ACTH.

Authors:  K E Andersson; B Arner; P Hedner; J L Mulder
Journal:  Acta Endocrinol (Copenh)       Date:  1972-04

6.  Tritium labelling of 8-lysine vasopressin and its purification by affinity chromatography on sepharose bound neurophysins.

Authors:  P Pradelles; J L Morgat; P Fromageot; M Camier; D Bonne; P Cohen; J Bockaert; S Jard
Journal:  FEBS Lett       Date:  1972-10-01       Impact factor: 4.124

7.  Corticotropin releasing activity of lysine vasopressin analogues.

Authors:  A Arimura; A V Schally; C Y Bowers
Journal:  Endocrinology       Date:  1969-03       Impact factor: 4.736

8.  Presence of corticotropin releasing factor-like immunoreactivity in hypophysial portal blood.

Authors:  D M Gibbs; W Vale
Journal:  Endocrinology       Date:  1982-10       Impact factor: 4.736

9.  Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors.

Authors:  D Butlen; G Guillon; R M Rajerison; S Jard; W H Sawyer; M Manning
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

10.  Vasopressin and neurophysin: high concentrations in monkey hypophyseal portal blood.

Authors:  E A Zimmerman; P W Carmel; M K Husain; M Ferin; M Tannenbaum; A G Frantz; A G Robinson
Journal:  Science       Date:  1973-11-20       Impact factor: 47.728

View more
  4 in total

Review 1.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

2.  Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumour-cell line.

Authors:  G Guillon; C J Kirk; M N Balestre
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

Review 3.  The role of intracellular messengers in adrenocorticotropin secretion in vitro.

Authors:  M S King; A J Baertschi
Journal:  Experientia       Date:  1990-01-15

4.  Isolated adrenocorticotropic hormone deficiency secondary to hypothalamic deficit of corticotropin releasing hormone.

Authors:  A Velardo; M Pantaleoni; G Zizzo; G Del Rio; F Coletta; C Carani; P Marrama
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.